Johnson & Johnson is advancing Alzheimer’s research through precision medicine, focusing on tau-targeting therapies like ...

Discover the groundbreaking AI-based platform that designs peptides to target and destroy previously 'undruggable' ...

ITM announces positive Phase 3 results for ITM-11 in neuroendocrine tumours, paving the way for a potential new treatment ...

New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Glox Therapeutics has received a portion of a £3 million fund to combat antimicrobial resistance in cystic fibrosis patients. The CF AMR Syndicate, which combines expertise from various sectors ...

Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients. Coherus BioSciences announced the final data from ...

Rigel Pharmaceuticals has announced the enrolment of the first patient in a Phase I trial evaluating fostamatinib for sickle cell disease. Fostamatinib, marketed as TAVALISSE ® in the US for chronic ...